Monthly information on share capital and company voting rights
Cellectis (Euronext Growth: CLLS) published its monthly information on share capital and voting rights as of December 31, 2025.
Rhea-AI Summary
Cellectis (Euronext Growth: CLLS) published its monthly information on share capital and voting rights as of December 31, 2025. The release lists the total number of shares and total voting rights recorded on that date.
- ISIN: FR0010425595
- Date: 12/31/2025
- Total shares: 100,339,441
- Total voting rights: 105,576,356
Contact details for media and investor relations were provided for further information.
Positive
- None.
Negative
- None.
Details
News Market Reaction – CLLS
In the Jan 6 session, CLLS declined 3.08%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Total shares
- 100,339,441
- Share capital as of 12/31/2025
- Total voting rights
- 105,576,356
- Voting rights as of 12/31/2025
Historical Context
-
Arbitral Tribunal decision partially terminating a license and dismissing other claims.
-
ASH 2025 Phase 1 NATHALI-01 eti-cel data with high ORR and CR rates.
-
Monthly disclosure of total shares and voting rights as of November 30, 2025.
-
Nature Communications paper on non-viral CssDNA gene insertion with high efficiency.
-
Q3 2025 results with multiple CAR-T efficacy data points and stronger revenue.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
isin financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
(Article 223-16 of General Regulation of the French financial markets authority)
PARIS, Jan. 05, 2026 (GLOBE NEWSWIRE) --
Listing market: Euronext Growth
ISIN code: FR0010425595
| Date | Total number of shares in the capital | Total number of voting rights |
| 12/31/2025 | 100,339,441 | 105,576,356 |
For further information on Cellectis, please contact:
Media contacts:
Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93
Investor Relations contact:
Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com
Attachment
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.